Research study Program year 2023 Source: CMS Open Payments

Phase III efficacy for obesity without T2DM

Research payments

$558,182

72 payments

Through program year 2023, $558,182 in research payments was reported against Phase III efficacy for obesity without T2DM, across 72 payments.

Paid by (largest first): Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH
ClinicalTrials.gov: No trial number was reported for this study

By program year

1 row

Year	Kind	Amount	Payments
2023	Research	$558,182	72

Breakdown

Who paid Research payments · program year 2023

Boehringer Ingelheim Pharmaceuticals, Inc. $437,566 39 payments
Boehringer Ingelheim International GmbH $120,616 33 payments

Who received the money Research payments · program year 2023

Emvenio Research Organisation paid for research $261,973 6 payments
Velocity Clinical Research Durham Organisation paid for research $33,500 2 payments
Meridian Clinical Research Organisation paid for research $15,862 4 payments
Lucas Research Organisation paid for research $10,368 2 payments
Alliance For Multispecialty Research LLC Organisation paid for research $10,000 1 payment
L-Marc Research Center Organisation paid for research $9,663 2 payments
East Coast Institute for Research LLC Organisation paid for research $9,578 3 payments
UF Health Shands Hospital Organisation paid for research $9,346 2 payments
Velocity Clinical Research Valparaiso Organisation paid for research $9,178 2 payments
Juno Research North Houston Organisation paid for research $9,173 2 payments

Usually the institution or organisation running the study, not a person.

Records

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

Principal investigators named

10 shown

Named on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.

What you are looking at

Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.